Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

The incidence of renal cell carcinoma (RCC) is increasing worldwide with an approximate 20% mortality rate. The challenge in RCC is the therapy-resistance. Cancer resistance to treatment employs multiple mechanisms due to cancer heterogeneity with multiple genetic and epigenetic alterations. These c...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fengzhi, Aljahdali, Ieman A. M., Zhang, Renyuan, Nastiuk, Kent L., Krolewski, John J., Ling, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359575/
https://www.ncbi.nlm.nih.gov/pubmed/34384473
http://dx.doi.org/10.1186/s13046-021-02026-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359575/
https://www.ncbi.nlm.nih.gov/pubmed/34384473
http://dx.doi.org/10.1186/s13046-021-02026-1

Ejemplares similares